Abstract
Objective:To observe the clinical effect and protection of vascular endothelium of Zhixinkang Capsule (ZXKC) in middle-aged and old people with unstable effort angina and hyperlipidemia.Methods: Sixty-five patients with unstable effort angina were randomly divided into ZXKC group (34 cases) and control group (31 cases). Conventional western medical therapy was given to both groups, with ZXKC group receiving additional ZXKC treatment. Data of 20 healthy persons were taken as normal group. Forty-eight patients with hyperlipidemia were divided into ZXKC group treated with ZXKC (31 cases) and control group treated with Yixintong (17 cases). The changes of clinical symptoms and laboratory indexes in all the patients were observed before and after treatment.Results: In patients with unstable effort angina, the efficacy of treatment of ZXKC, the withdrawal rate of nitroglycerin, the relieving of symptoms, the improvement of the electrocardiogram, the counts of circulating endothelial cells, the content of platelet P-selectin, the content of plasma endothelin (ET), the activity of Superoxide dismutase (SOD) and the activity of malonyldialdehyde (MDA) were all better than those in the control group. In patients with hyperlipidemia, there was no significant difference in lipids reduction between ZXKC group and the control group. In both groups, the total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), lipoprotein(a) [Lp(a)], ET, oxidized low density lipoprotein, MDA, arteriosclerotic index (AI) all lowered obviously, while the SOD, HDL-C and calcitonin gene-related peptide (CGRP) were all elevated markedly. In the ZXKC group, the nitric oxide (NO) increased significantly whereas the ET/CGRP and ET/NO decreased markedly. The total effective rate in symptom relieving, the markedly effective rate, the reduction of TC, ET and ET/CGRP, and the elevation of SOD in ZXKC group were all superior to those in the control group.Conclusion: ZXKC could effectively resist myocardial ischemia, relieve angina, reduce blood lipids, protect vascular endothelial cells, inhibit the activation of platelets, and resist lipid peroxidation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nomenclature and Diagnostic Standard for Ischemic Heart Disease. Combined Special Group on Nomenclature Standardization of the International Cardiology Association and WHO. J Chin Cardiovas Dis 1981;9(1): 75.
Guiding Principles of Clinical Research on New Chinese Drugs (Part II). Ministry of Health, PRC 1995: 171.
SU CL, SHENG SG. Modern Cardiology of TCM. Beijing: Beijing Science and Technology Press, 1997: 529–534.
CHEN KJ, LIAO JZ, XIAO ZX. Research on Cardio-cerebro-vascular Diseases. Shanghai: Shanghai Science and Technology Press, 1988: 318–319.
Guiding Principles in Clinical Research on New Chinese Drugs in Treating Senile Diseases. Administration of Pharmaceutic Affair, Ministry of Health, PRC. J Chin Med Pharm 1989; 4(3): 72.
YANG LX, ZHANG CD. Correlative research on circulating endothelial cells and plasma endothelin in patients with coronary heart disease. J Clin Cardiovasc Dis 1995; 11 (5): 273.
Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol1998;18 (9): 1393–1399.
Author information
Authors and Affiliations
Corresponding author
Additional information
study was funded by Natural Science Foundation of Shandong Province (No. Y97C22058)
Rights and permissions
About this article
Cite this article
Wen-gao, Z., Ting-xiang, Y., Fu-jun, G. et al. Study on effect of Zhixinkang Capsule in treating unstable effort angina and hyperlipidemia and its function in vascular endothelium protection. Chin. J. Integr. Med. 9, 25–30 (2003). https://doi.org/10.1007/BF02836349
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02836349